SYNTHETIC CHEMICAL DIVERSITY - SOLID-PHASE SYNTHESIS OF LIBRARIES OF C-2 SYMMETRICAL INHIBITORS OF HIV PROTEASE CONTAINING DIAMINO DIOL ANDDIAMINO ALCOHOL CORES
Gt. Wang et al., SYNTHETIC CHEMICAL DIVERSITY - SOLID-PHASE SYNTHESIS OF LIBRARIES OF C-2 SYMMETRICAL INHIBITORS OF HIV PROTEASE CONTAINING DIAMINO DIOL ANDDIAMINO ALCOHOL CORES, Journal of medicinal chemistry, 38(16), 1995, pp. 2995-3002
Solid phase synthesis of non-oligomeric organic compounds has been pur
sued for high-efficiency generation of large numbers of structurally d
iverse compounds for drug screening. Known as chemical diversity libra
ries or combinatorial libraries (when the synthesis is carried out in
a combinatorial fashion), these compounds can be used for de novo disc
overy of drug leads or for expedient structure-activity relationship (
SAR) studies. To expand the scope of solid phase synthesis beyond the
capability of the traditional method of solid phase synthesis for pept
ides, a strategy was developed for bi-directional solid phase synthesi
s starting with diamino alcohol or diamino diol core structures. The s
trategy relies on using bifunctional linkers to modify the core struct
ures, simultaneously protecting the hydroxyl group or the diol moiety
of the core and providing a carboxyl group for attachment of the modif
ied cores to a solid support. The two NH2 groups of the modified cores
attached to the solid support were then deprotected and reacted with
a wide variety of amine-reactive reagents (carboxylic acids, sulfonyl
chlorides, isocyanates, chloroformates, etc.) to extend the molecule i
n both directions. This strategy was successfully applied to automated
parallel synthesis of a library of C-2 symmetric inhibitors of HIV pr
otease containing the known symmetry-based diamino diol and diamino al
cohol core structures, thus enabling expedient access of large numbers
of analogs in this series. A library of over 300 discrete compounds w
as synthesized using this methodology in order to identify potent (IC5
0 < 100 nM) HIV protease inhibitors with reduced size. This paper desc
ribes the technical aspects of this technology.